Fully Booked

Early detection of lung cancer – the NELSON trial results in real-life practice

Chair: Jan van Meerbeeck Speaker: Harry De Koning

Lung cancer is still the deadliest and most expensive tumour entity in Europe. Most lung cancer patients present with already locally advanced or even metastazied stages at the time of primary diagnosis limiting curatively intended treatment options. Low dose CT screening for lung cancer provides a unique chance to detect patients already in early stages so that curation is much more likely. In September 2019, the results of Europe’s largest low dose CT screening study for lung cancer, the NELSON study, were presented at the IASLC conference in Toronto demonstrating a positive effect of low dose CT screening in a well-defined high-risk population compared to a control group without any screening. In order to translate evident clinical trial knowledge into national population-based screening programmes, clinicians need to be aware of the basic principles as well as the chances and potential pitfalls of low dose CT screening for lung cancer.

Educational aims

  • A detailed presentations of NELSON study results and discussion in the context of the existing evidence on low dose CT screening
  • Rasing awareness of core elements in a low dose CT screening programme for lung cancer
  • Outline of an implementation strategy for a national population-based low dose CT lung cancer screening programme


Lecture including case presentations


  • Available evidence on low dose CT lung cancer screening with a focus on the NELSON study results
  • Definition of adequate risk populations for low dose CT lung cancer screening
  • Essential infrastructure and processes for a local low dose CT screening programme
  • Implementation strategy for a national population-based low dose CT lung cancer screening programme

Learning outcomes

Following this course, participants will be able to:

  • Better appraise the current status of low dose CT lung cancer screening including benefits, potential harms, and open research topics.
  • Assess how a good local screening program should be structured.
  • Step-wise develop a national screening program.

What is a webinar?

The webinar closely simulates a lecture-based teaching experience. The speaker can interact with the audience, just as in a classroom setting.

This webinar comprises 45-minute lecture followed by a 15-minute question-and-answer sessions. During the webinar you will be asked to share your opinion on issues related to the topic using interactive polls. Your answers are not evaluated but participation is mandatory to obtain the CME credits.

All participants will be able to hear the lecturer and see the slides throughout the presentation. As a participant you will be able to pose questions or discuss ideas with the other participants via the text chat facility and the speaker will respond to the questions via the microphone.

Log in guidelines

To attend the webinar you will need to log in to an Adobe Connect platform. We will send you related login information one week before the webinar is due to commence.

In order to benefit from this live experience we advise that you ensure that your equipment is compatible with the technical specifications listed here:

It is also recommended that you perform a system test.

  • Please log in to the webinar 20 minutes before it is scheduled to commence. If you have any technical difficulties whilst trying to log in or during the session please contact e-learning@ersnet.org
  • Check Central European Time.
  • To achieve the best quality, we recommend to stop all other programmes and to avoid downloading anything from the internet during your connection to the lecture.
  • Please also ensure that your audio settings are not set to mute and adjust the volume to a comfortable level.

Target Audience

  • Adult Pulmonologist/Clinician
  • General Practitioner
  • Medical Student
  • Radiologist
  • Thoracic Surgeon

Diseases / Methods

Thoracic oncology

Contact e-learning@ersnet.org to be added to the waiting list.

Fully Booked